Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Harmony Biosciences Holdings (HRMY) Net Income (2019 - 2025)

Harmony Biosciences Holdings (HRMY) has disclosed Net Income for 7 consecutive years, with $22.5 million as the latest value for Q4 2025.

  • Quarterly Net Income fell 54.55% to $22.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $158.7 million through Dec 2025, up 9.07% year-over-year, with the annual reading at $158.7 million for FY2025, 9.07% up from the prior year.
  • Net Income hit $22.5 million in Q4 2025 for Harmony Biosciences Holdings, down from $50.9 million in the prior quarter.
  • In the past five years, Net Income ranged from a high of $87.9 million in Q3 2022 to a low of -$9.6 million in Q3 2021.
  • Historically, Net Income has averaged $31.8 million across 5 years, with a median of $31.9 million in 2023.
  • Biggest YoY gain for Net Income was 52385.19% in 2021; the steepest drop was 603.93% in 2021.
  • Year by year, Net Income stood at $22.7 million in 2021, then surged by 113.56% to $48.5 million in 2022, then tumbled by 72.81% to $13.2 million in 2023, then skyrocketed by 275.15% to $49.5 million in 2024, then crashed by 54.55% to $22.5 million in 2025.
  • Business Quant data shows Net Income for HRMY at $22.5 million in Q4 2025, $50.9 million in Q3 2025, and $39.8 million in Q2 2025.